Tirzepatide Dosage Chart & Schedule
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
Reported clinical use is once weekly with a slow titration - commonly referenced from 2.5 mg weekly, increasing by about 2.5 mg roughly every 4 weeks as tolerated, up to about 15 mg weekly.
Figures describe how Tirzepatide is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Once weekly
- Weekly total
- 2.5 mg
- Cycle
- ~4 weeks, then titrate
Referenced initiation dose; a lead-in for GI tolerability rather than a target.
- Frequency
- Once weekly
- Weekly total
- 7.5 mg
- Cycle
- Hold ~4 weeks per step
Mid-ladder step (2.5 -> 5 -> 7.5 mg) reached by stepping up about 2.5 mg every ~4 weeks.
- Frequency
- Once weekly
- Weekly total
- 10-15 mg
- Cycle
- Ongoing
Common target maintenance range in the approved regimen; 15 mg is the highest labeled step.
Two incretin pathways
- Activates both the GIP and GLP-1 receptors; an approximately 5-day half-life supports once-weekly dosing.
- SURMOUNT weight-loss trials reported notably large body-weight reductions at higher maintenance doses.
Approved brands
- Marketed as Mounjaro (type-2 diabetes) and Zepbound (weight management).
- Labeled titration runs from 2.5 mg up to 15 mg weekly.
Ready to run this protocol?
Dosing is only as good as the vial. Tirzepatide is third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Weekly schedule
A typical week on the maintenance protocol (Once weekly).
Dosing day Off
Tirzepatide reconstitution
Based on a standard 10 mg vial: with 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit ≈ 50 mcg.
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (2 mL) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe (~50 units for 2.5 mg).
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- A 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL, so 2.5 mg draws to about 50 units on a U-100 syringe.
- Higher steps exceed 1 mL at 5 mg/mL (e.g., 7.5 mg = 1.5 mL); reconstituting with less water raises mg/mL and keeps a single injection under 1 mL.
- Refrigerate the reconstituted solution and keep lyophilized powder cool and dark.
Tirzepatide dosing FAQ
How is tirzepatide titrated?
Commonly referenced as 2.5 mg weekly to start, then increases of about 2.5 mg roughly every 4 weeks as tolerated, toward a 10-15 mg weekly maintenance range.
Why not start at the target dose?
The lower starting dose is described as a way to limit gastrointestinal effects; 2.5 mg is generally treated as a lead-in rather than a maintenance dose.
Once weekly or daily?
Once weekly, consistent with the reported roughly 5-day half-life.
How much volume per shot?
From 10 mg in 2 mL (5 mg/mL): 2.5 mg = about 50 units, 5 mg = about 100 units. For higher doses a more concentrated mix avoids exceeding a 1 mL syringe.
Sources
Categories: GLP-1 & Metabolic · Status: Approved (see notes). This page is educational and for laboratory research use only; it is not medical advice.